FatPipe Just Got Its First Analyst. The $8 Target Hinges on Whether the Cash Flow Repeats.

An $80 million company just received the first real sell-side endorsement of its public life. On September 10, ROTH Capital initiated coverage of FatPipe (NASDAQ: FATN) with a Buy rating and an $8.00 price target, roughly 43% above the $5.61 where the stock opened. For most shareholders that is a non-event. For a microcap that has had almost no independent research since its April 2025 IPO, it is the first time anyone with a platform has said in writing what the business is worth.

FatPipe is a Salt Lake City maker of software-defined wide area network (SD-WAN) software — code that lets a company move traffic across several internet connections at once, so it keeps operating when one link fails — wrapped in a cybersecurity layer. It holds 13 U.S. patents and sells through more than 200 resellers. None of that is new. What is new is that an analyst whose job is to hunt under-covered growth names has now put a target on it.

The numbers underneath already turned

The interesting part is not the note itself but the operating record ROTH was looking at, because that record quietly improved before anyone in a suit said so. In the fiscal year that ended in March, revenue rose 18% to $19.2 million. Then it accelerated: the June quarter grew 28% year over year to $5.03 million, following a fiscal fourth quarter that grew 90%. The company frames the driver as recurring billings, which rose 56% in that fourth quarter on renewals and new customers.

More important for an investor taught to distrust clickbait is that FatPipe turned consistently profitable. Adjusted EBITDA reached a 28% margin for the full year and 25.6% in the latest quarter, and the June quarter produced $1.2 million of net income, beating the tiny consensus that exists. For a software vendor with gross margins above 90%, that is the shape of a business with operating leverage, not a story propped up by hype.

The honest catch: the cash flow still has to prove itself

Here is where I slow down, because this is the metric that decides whether $8 is a number or a hope. ROTH's own thesis leans on resilience and security demand, but the hard bridge for a microcap is free cash flow — does the profit actually land in the bank, and does it repeat? On that, the record is one quarter, not a trend. Zacks Small-Cap Research noted $5.2 million of free cash flow in the March 2026 quarter, the big Q4. But the cash pile has drifted down, from $5.9 million last June to $5.2 million at the end of the fiscal year, against $4.6 million of debt. In other words, the profitability has not yet compounded into a growing cash cushion — the strong FCF was a single-quarter reading, and one strong quarter is not durability.

It is also worth being blunt about whose opinion this is. "Coverage initiated, Buy, $8" reads like a fact, but it is one firm's estimate. The handful of firms that now follow FatPipe disagree — one of them still rates it a sell. Polled consensus lands around a $9 to $10 average target, which tells you the $8 is not wildly out of line with a modestly bullish crowd, but it is not a guarantee of fair value either. This is a sub-$100 million company with a 2.8 beta, thin volume, and institutional holders whose positions are measured in a few hundred thousand dollars. ROTH underwriting and ROTH research often travel together on microcaps, so take the endorsement as a signal of interest, not as a price command.

What that makes the stock worth

Put the valuation on the table so it is concrete. At roughly $80 million in market value and consensus fiscal-2027 revenue around $27 million, the stock trades near three times forward sales. On the ~$0.44 a share the sell side models for the current year, that is a low-teens forward multiple. That is not dirt cheap, and it is not a bubble — it is a reasonable, but not bargain, price for a small software company growing in the high 20s with real margins.

That is why I would not chase the 43% printed in the headline as though ROTH's target were a coupon. The stock already moved from a $1.31 low to roughly $5.60 before this note appeared, so a good part of the rerating has happened. The disciplined read is to let the proof path do the work: watch whether recurring billings keep compounding at the 25%-plus organic clip and, above all, whether the free cash flow that appeared in one quarter shows up in a second. If it does, an improving business that was invisible to the Street for seventeen months starts to look hard to ignore. If it does not — if the strong Q4 was a one-time spike, a renewals lump, or a working-capital quirk — then the $8 target is a microcap analyst's estimate built on a picture the cash flow has not confirmed yet.

A single initiation note is not a license to buy. It is permission to look. The business genuinely improved before anyone handed out a price target; whether that improvement converts into bankable cash, quarter after quarter, is the test that separates this from thousands of other small-cap re-rating stories.